Anastellin, the angiostatic fibronectin peptide, is a selective inhibitor of lysophospholipid signaling

Molecular Cancer Research

Volumn 7, Issue 2, 2009, Pages 255-265

  Ambesi, Anthony ^a   McKeown Longo, Paula J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTELLIN; FIBRONECTIN; GROWTH FACTOR RECEPTOR; LYSOPHOSPHOLIPID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; RHO KINASE; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CYTOSKELETON; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRESS FIBER;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOGENESIS INHIBITORS; ANGIOSTATIC PROTEINS; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBRONECTINS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LYSOPHOSPHOLIPIDS; MICROCIRCULATION; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RHO-ASSOCIATED KINASES; S PHASE; SIGNAL TRANSDUCTION; SKIN;

EID: 61349092340     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0195     Document Type: Article

References (61)

1. Hynes RO. Cell matrix adhesion in vascular development. J Thromb Haemost 2007;5:32-40.
2. Goetzl EJ, An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J 1998;12:1589-98.
3. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarkerfor ovarian and other gynecologic cancers. JAMA 1998;280:719-23.
4. 13. Science 1998;280:2112-4.
5. Fukuhara S, Murga C, Zohar M, Igishi T, Gutkind JS. A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. J Biol Chem 1999;274:5868-79.
6. Booden MA, Siderovski DP, Der CJ. Leukemia-associated Rho guanine nucleotide exchange factor promotes Gαq-coupled activation of RhoA. Mol Cell Biol 2002;22:733-8.
7. 12 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF. Proc Natl Acad Sci U S A 2003;100:733-8.
8. 12/13-induced signals to Rho GTPase. Cell Signal 2004;16:201 -9.
9. Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002;277:39436 -42.
10. van Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006;26:5015-22.
11. Tanaka M, Okudaira S, Kishi Y, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006;281:25822-30.
12. Panetti JS. Differential effects of sphingosine 1-phosphate and lysophospha- tidic acid on endothelial cells. Biochim Biophys Acta 2002;1582:190-6.
13. Sabbadini RA. Targeting sphingosine-1-phosphate for cancer therapy. Br J Cancer 2006;95:1131 -5.
14. Kono M, Mi Y, Liu Y, et al. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem 2004;279:29367-73.
15. Visentin B, Vekich JA, Sibbald BJ, et al. Validation of an anti-sphingosine-1- phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006;9:225 -38.
16. LaMontagne K, Littlewood-Evans A, Schnell C, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006;66:221 -31.
17. Pasqualini R, Bourdoulous S, Looivunen E, Woods VL, Jr., Ruoslahti E. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med 1996;2:1197-203.
18. Yi M, Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci U S A 2001;98:620-4.
19. 1 arrest in human microvessel endothelial cells. Cancer Res 2005;65:148-56.
20. Daub H, Wallasch CLA, Herrlich A, Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1997;16:7032-44.
21. Wang L, Cummings R, Zhao Y, et al. Involvement of phospholipase D2 in lysophosphatidate-induced transactivation ofplatelet-derived growth factor receptor-β in human bronchial epithelial cells. J Biol Chem 2003;278:39931 -40.
22. Tanimoto T, Jin Z-G, Berk BC. Transactivation of vascular endothelial growth factor (VEGF)receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem 2002;277:42997-3001.
23. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 2004;92:949-66.
24. Spiegel S, Milstien S. Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways. Biochem Soc Trans 2003;31:1216-9.
25. Yi M, Sakai T, Fassler R, Ruoslahti E. Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci U S A 2003;100:11435-8.
26. Bourdoulous S, Orend G, MacKenna DA, Pasqualini R, Ruoslahti E. Fibronectin matrix regulates activation of RHO and CDC42 GTPases and cell cycle progression. J Cell Biol 1998;143:267-76.
27. Mercurius K, Morla A. Cell adhesion and signaling on the fibronectin 1st type III repeat; requisite roles for cell surface proteoglycans and integrins. BMC Cell Biol 2001;2:18-30.
28. Klein RM, Zheng M, Ambesi A, van de Water L, McKeown-Longo PJ. Stimulation of extracellular matrix remodeling by the first type III repeat in fibronectin. J Cell Sci 2003;116:4663-74.
29. van Meeteren LA, Moolenaar WH. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 2007;46:145-60.
30. Argraves KM, Argraves WS. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res 2007;48:2325-33.
31. Sukocheva O, Wadham C, Holmes A, et al. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol 2006;173:301-10.
32. Gschwin A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 2002;62:6329 -36.
33. Budnik LT, Brunswig-Spickenheier B, Mukhopadhyay AK. Lysophos-phatidic acid signals through mitogen-activated protein kinase-extracellular signal regulated kinase in ovarian theca cells expressing the LPA1/edg2- receptor: involvement of a nonclassical pathway. Mol Endocrinol 2003;17:1593 -606.
34. Yokomori H, Yoshimura K, Funakoshi S, et al. Rho modulates hepatic sinusoidal endothelial fenestrae via regulation of the actin cytoskeleton in rat endothelial cells. Lab Invest 2004;84:857 -64.
35. Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vascul Pharmacol 2002;39:187-99.
36. van Nieuw Amerongen GP, Vermeer MA, van Hinsbergh VW. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 2000;20:E127 -33.
37. Kou R, Igarashi J, Michel T. Lysophosphatidic acid and receptor- mediated activation of endothelial nitric-oxide synthase. Biochemistry 2002;41:4982-8.
38. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J Biol Chem 2003;278:37895 -901.
39. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65:3967 -79.
40. Gao M, Craig D, Lequin O, Campbell ID, Vogel V, Schulten K. Structure and functional significance of mechanically unfolded fibronectin type III1 intermediates. Proc Natl Acad Sci U S A 2003;100:14784-9.
41. Schor SL, Ellis IR, Jones S, et al. Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells. Cancer Res 2003;63:8827-36.
42. Liao Y-F, Gotwals PJ, Koteliansky VE, Sheppard D, van de Water L. The EIIIA segment of fibronectin is a ligand for integrins α9β1 and α4β1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem 2002;277:14467 -74.
43. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;276:10229 -33.
44. Mitsi M, Hong Z, Costello CE, Nugent MA. Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites. Biochemistry 2006;45:10319-28.
45. Wijelath ES, Rahman S, Namekata M, et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 2006;99:863-0.
46. Kishi Y, Okudaira S, Tanaka M, et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 2006;281:17492 -500.
47. Xie Y, Gibbs TC, Mukhin YV, Neier KE. Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J Biol Chem 2002;277:32516-26.
48. Chen M, O'Connor KL. Integrin α6β4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 2005;24:5125-30.
49. Ren J, Xiao YJ, Singh LS, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006;66:3006 -14.
50. Yamada T, Sato K, Komachi M, et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 2004;279:6595 -605.
51. Morla A, Zhang Z, Ruoslahti E. Superfibronectin is a functionally distinct form of fibronectin. Nature 1994;367:193 -6.
52. Akerman ME, Pilch J, Peters D, Ruoslahti E. Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. Proc Natl Acad Sci U S A 2005;102:2040-5.
53. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006;118:1331 -9.
54. Zardi L, Carnemolla B, Siri A, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987;6:2337 -42.
55. Borsi L, Carnemolla B, Castellani P, et al. Monocloncal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed humancells. J Cell Biol 1987;104:595 -600.
56. Carnemolla B, Balza E, Siri A, et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989;108:1139 -48.
57. Boudreau NJ, Varner JA. The homeobox transcription factor Hox D3 promotes integrin α5β1 expression and function during angiogenesis. J Biol Chem 2004;279:4862-8.
58. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993;119:1079-91.
59. Kim S, Harris M, Varner JA. Regulation of integrin αvβ3- mediated endothelial cell migration and angiogenesis by integrin α5β1 and protein kinase A. J Biol Chem 2000;275:33920 -8.
60. 5 integrin-deficient mice. Development 1993;119:1093 -105.
61. Astrof S, Crowley D, Hynes RO. Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin. Dev Biol 2007;311:11 -24.